Jay Pharma Inc., a company dedicated to developing innovative, evidence-based medicines to address unmet patient needs in cancer care, today announced that George A. Kegler Jr. plans to join Jay Pharma’s Board of Directors upon the closing of the anticipated merger transaction with Ameri Holdings (“Ameri”). Mr. Kegler also plans to serve as Chair of Jay Pharma’s Audit Committee.
From 2013 to 2019, Mr. Kegler held senior leadership positions at Mallinckrodt plc (“Mallinckrodt”), a leading global specialty pharmaceutical company. Mr. Kegler served as interim Chief Financial Officer, Vice President of Finance, and interim President of Mallinckrodt’s Specialty Generics business. From 2008 to 2012, Mr. Kegler served as the Chief Financial Officer of Convatec, a private equity owned company that was originally part of Bristol-Myers Squibb. Prior to Convatec, Mr. Kegler worked in various finance roles within Bristol-Myers Squibb including commercial, international, technical operations, and research and development.
George A. Kegler Jr.
“Mr. Kegler will offer strong financial expertise to Jay Pharma as we build a world-class board of directors with relevant skills and experience,” said Dave Johnson, who plans to join Jay Pharma as Chairman and CEO upon the closing of the Ameri merger transaction. “His decades-long healthcare business knowledge will be an incredible asset to our team, and we believe he will add immense value as future Chair of Jay Pharma’s Audit Committee, while helping to build a foundation to support and propel Jay Pharma’s rapid expansion.”
“I look forward to joining Jay Pharma’s leadership, scientific advisors, and board as we work together to positively impact the lives of persons impacted by cancer,” said Mr. Kegler. “To be a part of an emerging industry is very exciting to me. I admire Jay Pharma’s success in identifying and developing novel approaches to cancer care and I look forward to providing strategic guidance to advance its business.”
This press release contains certain “forward-looking statements”. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Jay Pharma. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Jay Pharma cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Jay Pharma will be not be able to obtain market adoption of its products, Jay Pharma will not obtain appropriate or necessary governmental approvals to market these or other potential products, Jay Pharma may not be able to obtain anticipated funding for its development projects or other needed funding, and Jay Pharma may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Jay Pharma does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware